Coherus BioSciences, Inc.

NasdaqGM:CHRS Stock Report

Market Cap: US$170.5m

Coherus BioSciences Future Growth

Future criteria checks 1/6

Coherus BioSciences's earnings are forecast to decline at 90.4% per annum while its annual revenue is expected to grow at 5.8% per year. EPS is expected to decline by 50.9% per annum. Return on equity is forecast to be 42.6% in 3 years.

Key information

-90.4%

Earnings growth rate

-50.9%

EPS growth rate

Biotechs earnings growth27.8%
Revenue growth rate5.8%
Future return on equity42.6%
Analyst coverage

Good

Last updated16 Dec 2024

Recent future growth updates

Recent updates

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Dec 16

Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Nov 06
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Sep 22
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 13

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Aug 07
Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 31

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

May 23
Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 21

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Jan 17

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Dec 20
Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

May 13
The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Sep 19

Coherus: 2022 Is In Many Ways A Make Or Break Year

Aug 24

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Aug 03

Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer

Jul 06

Earnings and Revenue Growth Forecasts

NasdaqGM:CHRS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026318-45-73-825
12/31/2025279-71-34-385
12/31/202425610-64-877
9/30/20243040-63-62N/A
6/30/2024308-29-56-54N/A
3/31/2024302-59-154-153N/A
12/31/2023257-238-176-175N/A
9/30/2023211-217-229-262N/A
6/30/2023182-264-213-245N/A
3/31/2023183-271-225-256N/A
12/31/2022211-292-246-241N/A
9/30/2022239-279-231-193N/A
6/30/2022276-230-180-143N/A
3/31/2022304-210-121-93N/A
12/31/2021327-287-39-37N/A
9/30/2021364-232-9048N/A
6/30/2021395-165-6082N/A
3/31/2021443-76-16142N/A
12/31/2020476132139154N/A
9/30/2020489162113139N/A
6/30/2020487181125146N/A
3/31/20204351458499N/A
12/31/2019356901528N/A
9/30/2019232-12-38-37N/A
6/30/2019121-118-136-134N/A
3/31/201937-185-184-183N/A
12/31/2018N/A-209-160-159N/A
9/30/2018N/A-196-143-142N/A
6/30/2018N/A-196N/A-141N/A
3/31/20181-208N/A-161N/A
12/31/20172-238N/A-200N/A
9/30/20172-265N/A-257N/A
6/30/2017165-122N/A-278N/A
3/31/2017178-137N/A-250N/A
12/31/2016190-127N/A-253N/A
9/30/2016199-104N/A-160N/A
6/30/201644-259N/A-158N/A
3/31/201637-248N/A-151N/A
12/31/201530-223N/A-108N/A
9/30/201526-200N/A-147N/A
6/30/201535-137N/A-92N/A
3/31/201533-103N/A-72N/A
12/31/201431-87N/A-24N/A
9/30/201426-73N/A14N/A
6/30/201410-86N/A41N/A
3/31/20146-70N/A37N/A
12/31/20133-54N/A15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CHRS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CHRS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CHRS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CHRS's revenue (5.8% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: CHRS's revenue (5.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CHRS's Return on Equity is forecast to be very high in 3 years time (42.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 00:01
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Coherus BioSciences, Inc. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Balaji PrasadBarclays
Balaji PrasadBarclays